Benefit of adjuvant BMA (bone modifying agents, meaning bisphosphonates and denosumab) in eBC

Podcast 2021021
Download attendance certificate
e-ESO podcast channel
Listen on Spotify
Listen on Apple
Listen on Google

Questions:

  1. What is the recommendation for use of bisphosphonates in eBC? Which agents? How long? To which patients? 
  2. What is the benefit of adjuvant bisphosphonates in eBC (breast cancer - related outcomes and other benefit)? 
  3. What is the recommendation for use of denosumab in eBC? 
  4. What are the data to support these recommendations for practice? 
Expert
Michael Gnant'
Michael Gnant
Comprehensive Cancer Center Vienna
Vienna, Austria
29
Jul 2021
Download attendance certificate
e-ESO podcast channel
Listen on Spotify
Listen on Apple
Listen on Google
Related e-Sessions:
ESCO logo
ESCO is the College of the European School of Oncology for ESO students offering a structured educational pathway to enhance their oncology careers.
Ulm university
Ulm university
The e-ESO e-Sessions are part of the Master-Online Study Program Advanced Oncology of Ulm University
www.uni-ulm.de
The mastermind winners of
e-Session 660
  1. Reda Mohamed Husseen
  2. Marina Puchinskaya
  3. Zacharoula Sidiropoulou
ESO & OncoAlert
e-Eso Onco alert
Oncology education together via social media
facebook eso twitter eso instagram eso